
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences has demonstrated robust growth in its transcatheter aortic valve replacement (TAVR) segment, achieving a 10.6% increase in sales during the latest quarter, marking the strongest growth performance since late 2023. The company's expectations for fiscal year 2025 have been revised upwards, with anticipated revenue growth now projected at the high end of the 9-10% range and earnings per share (EPS) expected to rise to $2.56-$2.62, indicating strong financial momentum and confidence in continued growth. Key drivers of this outlook include significant growth in tricuspid and mitral valve procedures, along with a strong focus on aortic stenosis treatment among physicians, further supporting accelerated TAVR growth forecasts for the upcoming year.
Bears say
The financial outlook for Edwards Lifesciences appears negative due to several key factors that could hinder future growth. The anticipated expansion of the transcatheter aortic valve replacement (TAVR) market may not meet investor expectations, with potential challenges including slower adoption rates of upcoming technology and increased competition that could impact market share and pricing. Additionally, delays in the innovation pipeline for tricuspid and mitral valve repair products pose risks to the company's sales growth, as substantiated clinical data is necessary for wider acceptance and successful product launches.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares